KR20160096721A - 필라델피아 염색체-음성 골수증식 증후군의 관리를 위한 히스톤 디아세틸라아제 억제제의 용도 - Google Patents

필라델피아 염색체-음성 골수증식 증후군의 관리를 위한 히스톤 디아세틸라아제 억제제의 용도 Download PDF

Info

Publication number
KR20160096721A
KR20160096721A KR1020167020675A KR20167020675A KR20160096721A KR 20160096721 A KR20160096721 A KR 20160096721A KR 1020167020675 A KR1020167020675 A KR 1020167020675A KR 20167020675 A KR20167020675 A KR 20167020675A KR 20160096721 A KR20160096721 A KR 20160096721A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
composition according
negative myeloproliferative
myeloproliferative syndrome
philadelphia chromosome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167020675A
Other languages
English (en)
Korean (ko)
Inventor
티지아노 올도니
파올로 마스카니
알렉산드로 램발디
티지아노 바르부이
Original Assignee
이탈파마코 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이탈파마코 에스.피.에이. filed Critical 이탈파마코 에스.피.에이.
Publication of KR20160096721A publication Critical patent/KR20160096721A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020167020675A 2008-09-29 2009-09-21 필라델피아 염색체-음성 골수증식 증후군의 관리를 위한 히스톤 디아세틸라아제 억제제의 용도 Ceased KR20160096721A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITMI2008A001720A IT1392908B1 (it) 2008-09-29 2008-09-29 Uso degli inibitori delle istone-deacetilasi per la cura di sindromi mieloproliferative philadelphia-negative
ITMI2008A001720 2008-09-29
US19328308P 2008-11-13 2008-11-13
US61/193,283 2008-11-13
PCT/EP2009/062214 WO2010034693A1 (en) 2008-09-29 2009-09-21 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020117008487A Division KR20110069075A (ko) 2008-09-29 2009-09-21 필라델피아 염색체-음성 골수증식 증후군의 관리를 위한 히스톤 디아세틸라아제 억제제의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177031565A Division KR20170124640A (ko) 2008-09-29 2009-09-21 필라델피아 염색체-음성 골수증식 증후군의 관리를 위한 히스톤 디아세틸라아제 억제제의 용도

Publications (1)

Publication Number Publication Date
KR20160096721A true KR20160096721A (ko) 2016-08-16

Family

ID=40810309

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020167020675A Ceased KR20160096721A (ko) 2008-09-29 2009-09-21 필라델피아 염색체-음성 골수증식 증후군의 관리를 위한 히스톤 디아세틸라아제 억제제의 용도
KR1020117008487A Ceased KR20110069075A (ko) 2008-09-29 2009-09-21 필라델피아 염색체-음성 골수증식 증후군의 관리를 위한 히스톤 디아세틸라아제 억제제의 용도
KR1020177031565A Ceased KR20170124640A (ko) 2008-09-29 2009-09-21 필라델피아 염색체-음성 골수증식 증후군의 관리를 위한 히스톤 디아세틸라아제 억제제의 용도

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020117008487A Ceased KR20110069075A (ko) 2008-09-29 2009-09-21 필라델피아 염색체-음성 골수증식 증후군의 관리를 위한 히스톤 디아세틸라아제 억제제의 용도
KR1020177031565A Ceased KR20170124640A (ko) 2008-09-29 2009-09-21 필라델피아 염색체-음성 골수증식 증후군의 관리를 위한 히스톤 디아세틸라아제 억제제의 용도

Country Status (17)

Country Link
US (4) US20110294892A1 (enExample)
EP (1) EP2344253B1 (enExample)
JP (1) JP2012504112A (enExample)
KR (3) KR20160096721A (enExample)
CN (1) CN102164638A (enExample)
BR (1) BRPI0913699A2 (enExample)
CA (1) CA2738081C (enExample)
CY (1) CY1115255T1 (enExample)
DK (1) DK2344253T3 (enExample)
ES (1) ES2478827T3 (enExample)
HR (1) HRP20140499T1 (enExample)
IT (1) IT1392908B1 (enExample)
PL (1) PL2344253T3 (enExample)
PT (1) PT2344253E (enExample)
SI (1) SI2344253T1 (enExample)
SM (1) SMT201400087B (enExample)
WO (1) WO2010034693A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8217079B2 (en) * 2010-03-26 2012-07-10 Italfarmaco Spa Method for treating Philadelphia-negative myeloproliferative syndromes
WO2015165975A1 (en) * 2014-04-29 2015-11-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating myeloid neoplasias
TW201821105A (zh) 2016-10-20 2018-06-16 美商弗瑪治療公司 使用ｈｄａｃ１１抑制劑之方法
US10865328B2 (en) * 2017-02-20 2020-12-15 Dow Silicones Corporation Room-temperature-curable silicone composition and electric/electronic apparatus
US11535607B2 (en) 2018-04-20 2022-12-27 Valo Health, Inc. Isoindolines as HDAC inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
ITMI20030063A1 (it) * 2003-01-17 2004-07-18 Italfarmaco Spa Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico.
ITMI20030064A1 (it) * 2003-01-17 2004-07-18 Italfarmaco Spa Uso dei derivati dell'acido idrossamico per la preparazione
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
WO2006063294A2 (en) * 2004-12-09 2006-06-15 Kalypsys, Inc. Novel inhibitors of histone deacetylase for the treatment of disease
TW200730485A (en) * 2005-07-29 2007-08-16 Kalypsys Inc Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
AU2006321710A1 (en) 2005-12-09 2007-06-14 Massachusetts Institute Of Technology Methods for identifying and targeting tumor stem cells based on nuclear morphology
US20080242648A1 (en) * 2006-11-10 2008-10-02 Syndax Pharmaceuticals, Inc., A California Corporation COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
US20110104177A1 (en) * 2006-12-28 2011-05-05 The Johns Hopkins University Histone deacetylase inhibitors, combination therapies and methods of use

Also Published As

Publication number Publication date
HRP20140499T1 (hr) 2014-07-04
US20110294892A1 (en) 2011-12-01
IT1392908B1 (it) 2012-04-02
US20210128512A1 (en) 2021-05-06
US9522127B2 (en) 2016-12-20
EP2344253A1 (en) 2011-07-20
ITMI20081720A1 (it) 2010-03-30
ES2478827T3 (es) 2014-07-23
KR20110069075A (ko) 2011-06-22
EP2344253B1 (en) 2014-04-23
BRPI0913699A2 (pt) 2017-06-13
CA2738081C (en) 2017-11-07
US20170049740A1 (en) 2017-02-23
PT2344253E (pt) 2014-07-16
SMT201400087B (it) 2014-09-08
US20140039059A1 (en) 2014-02-06
PL2344253T3 (pl) 2014-09-30
DK2344253T3 (da) 2014-06-16
SI2344253T1 (sl) 2014-08-29
CA2738081A1 (en) 2010-04-01
WO2010034693A1 (en) 2010-04-01
CY1115255T1 (el) 2017-01-04
CN102164638A (zh) 2011-08-24
KR20170124640A (ko) 2017-11-10
JP2012504112A (ja) 2012-02-16

Similar Documents

Publication Publication Date Title
US20210128512A1 (en) Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes
Bradley et al. Histone deacetylases in bone development and skeletal disorders
AU2003219803B8 (en) Method of treating TRX mediated diseases
CN109072186B (zh) 利用前列腺素e2进行肌肉再生的组合物和方法
EP3582814B1 (en) Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
WO2018227138A1 (en) Compositions and methods for preventing or treating muscle conditions
AU2018392985A1 (en) Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
JP2008500374A (ja) 自己炎症性疾患の処置のためのｉｃｅインヒビター
Hong et al. A novel role of lactate: promotion of Akt-dependent elongation of microglial process
Xu et al. Cyclosporine A stimulated hair growth from mouse vibrissae follicles in an organ culture model
Pan et al. Holomycin, a novel NLRP3 inhibitor, attenuates cartilage degeneration and inflammation in osteoarthritis
Wu et al. Targeting IRE1α improves insulin sensitivity and thermogenesis and suppresses metabolically active adipose tissue macrophages in male obese mice
US8217079B2 (en) Method for treating Philadelphia-negative myeloproliferative syndromes
Ra et al. Betulin suppressed interleukin-1β-induced gene expression, secretion and proteolytic activity of matrix metalloproteinase in cultured articular chondrocytes and production of matrix metalloproteinase in the knee joint of rat
CN113577051A (zh) 一种维拉帕米在制备保护软骨细胞缓解骨关节炎的产品中的应用
Yoshida et al. Effect of a nonprotein bioactive agent on the reduction of cyclooxygenase-2 and tumor necrosis factor–α in human intervertebral disc cells in vitro
US20230121771A1 (en) A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent
US20240374569A1 (en) Hdac3 inhibitors for the treatment of langerhans cell histiocytosis and langerhans cell sarcoma
ES2241182T3 (es) Procedimiento de inhibicion de la produccion de citocinas.
US11980635B2 (en) Methods of oral administration of protocatechuic acid for treating or reducing the severity of a joint injury or disease
US8546382B2 (en) Methods for enhancing hematopoietic progenitor cell engraftment
KR20250124466A (ko) 스트레스로 유도된 배양보조세포를 통한 자연살해세포의 효과적인 활성화 방법 및 이의 용도
HK40019900B (en) Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
HK40019900A (en) Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160727

Application number text: 1020117008487

Filing date: 20110414

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160729

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160823

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170412

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160823

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170412

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170213

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20170804

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170712

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20170412

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170213

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20160823

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20171031

Application number text: 1020117008487

Filing date: 20110414